Adaptimmune’s Tecelra is the first TCR cell therapy to reach the U.S. market, but arrives with only modest sales expectations.

The Food and Drug Administration on Thursday approved a new type of cellular medicine, clearing a therapy developed by the biotechnology company Adaptimmune for a rare soft tissue cancer called synovial sarcoma.

First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer | BioPharma Dive